Follow this innovation
[ via 
] [?]
Novel Thin Film Protein Drug Delivery Device
University of California System: University of California, San Francisco
posted on 10/27/2011
Chronic diseases often require long-term treatment strategies that rely on repeated injections. These delivery mechanisms, characterized by decreased bioavailability and highly variable drug exposure, constitute significant inconvenience and cost to patients by requiring frequent office visits and increasing potential complications from frequent injections. For example, treatment of advanced macular degeneration (AMD) requires injections of anti-VEGF proteins into the eye once every four weeks, potentially leading to complications such as retinal detachment and tearing. These limitations have spurred efforts to create new platforms for longer-term, constant delivery of therapeutics in the body, such as osmotic pumps and microparticle delivery systems. These systems currently offer sustained release of therapeutics on the order of several weeks. However, while the current offerings are effective in the release of small-molecule therapeutics, their ability to sustain longer-term, controlled release of large protein-based biologics is severely limited.
Suggested Uses
- For the treatment of chronic eye diseases such as AMD, diabetic macular edema
- For the treatment of rheumatoid arthritis
- For the treatment of multiple sclerosis
Advantages
- Longer therapeutics window for protein biologics
- Technology offers constant delivery rates for at least 4 months
- Significantly decreased the frequency of injections, and subsequent injection-related side effects and compliance issues
- Greatly reduces treatment costs
Detailed Description
UCSF inventors have recently created an improved chronic drug delivery system based on biodegradable thin film nanotechnology. This system has the potential to package therapeutic amounts of bioactive proteins in an injectable – device, and to release protein therapeutics at a constant rate for several months. As a proof-of-concept, the inventors have demonstrated that their biodegradable thin film technology can release the large proteins such as bovine serum albumin and immunoglobulin at a steady rate for at least 4 months after implantation or injection. The technology has the potential to significantly improve treatment regiment for a number of chronic diseases treated by protein therapeutics, such as AMD, DME, rheumatoid arthritis, or multiple sclerosis.
Next Steps: The inventors are currently testing their drug delivery platform for the treatment of AMD.
File Number: 22024
| Copyright: | ©2011, The Regents of the University of California |
|---|
This innovation currently is not available for online licensing. Please contact Eileen Lee at University of California System: University of California, San Francisco for more information.
request more info
ProfileFind more innovations
